serpin peptidase inhibitor, clade C (antithrombin), member 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and Health Canada (Santé Canada) (HCSC). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

See the legend for more information about drug label sources and PGx Levels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA, HCSC or other Medicine Agencies around the world - please contact feedback.

last updated 10/29/2015

2. European Medicines Agency (EMA) for eltrombopag and F5, SERPINC1

Actionable PGx


The EMA European Public Assessment Report (EPAR) highlights that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).

There's more of this label. Read more.

last updated 01/26/2015

3. Pharmaceuticals and Medical Devices Agency, Japan (PMDA) for eltrombopag and SERPINC1

Actionable PGx


The PMDA package insert for eltrombopag notes that caution should be taken when administering the drug to patients with risk factors for thromboembolism, including antithrombin III (AT III; SERPINC1 gene) deficiency and antiphospholipid antibody syndrome, as these patients are at a further increased risk for thromboembolism when receiving eltrombopag.

There's more of this label. Read more.

last updated 06/08/2015

6. Health Canada Santé Canada (HCSC) for ethinyl estradiol, norelgestromin and F2, F5, MTHFR, PROC, PROS1, SERPINC1

Actionable PGx


The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the MTHFR gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.

There's more of this label. Read more.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help


Alternate Names:  AT3; antithrombin (aa 375-432); antithrombin III; coding sequence signal peptide antithrombin part 1; signal peptide antithrombin part 1
Alternate Symbols:  ATIII; MGC22579
PharmGKB Accession Id: PA35026


Cytogenetic Location: chr1 : q25.1 - q25.1
GP mRNA Boundary: chr1 : 173872942 - 173886516
GP Gene Boundary: chr1 : 173869942 - 173896516
Strand: minus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Common Pathway - (Reactome via Pathway Interaction Database)
  2. Glypican 1 network - (Pathway Interaction Database NCI-Nature Curated)
No related genes are available

Curated Information ?

No related diseases are available

Publications related to SERPINC1: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstetrics and gynecology. 2008. Johnson Julia V, et al. PubMed


NCBI Gene:
UCSC Genome Browser:
RefSeq RNA:
RefSeq Protein:
RefSeq DNA:
ANT3_HUMAN (P01008)
Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches